Exploring of Recent pharmaceutical applications of Sildenafil in medicine: review article
Abstract
Sildenafil (SIL), a phosphodiesterase enzyme 5 (PDE5) inhibitor, has become a prominent molecule for the erectile dysfunction (ED) treatment. It has assumed a major role in the treatment of this disease due to the demonstrated efficacy, ease of use, good tolerability, and positive impact on the quality of life of patients. SIL has multiple pharmacological actions that grasp the researchers’ attention due to its various pharmaceutical applications. In addition to its efficacy in treating erectile dysfunction (ED), SIL is extensively employed in the treatment of intrauterine growth retardation (IUGR), benign prostatic hypertrophy (BPH), Eisenmenger's syndrome and Mountain sickness, kidney diseases, pulmonary arterial hypertension. Furthermore, SIL also exhibits promise antiproliferative, anti-Alzheimer, and anti-inflammatory properties. Finally, the pharmacodynamics, pharmacokinetics, drug interactions, and SIL toxicity were investigated. The adequate pharmacokinetic properties of SIL and the diverse therapeutic applications have encouraged researchers to generate new applications that have either been approved by the FDA or are currently undergoing clinical trials like osteoarthritis (OA), COVID-19, female urinary incontinence (UI) and Maternally Inherited Leigh syndrome (MILS).
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.